| 商品名称 | Stayveer |
|---|
| 适用类别 | Human |
|---|
| 治疗领域 | Hypertension, Pulmonary;Scleroderma, Systemic |
|---|
| 通用名/非专利名称 | bosentan monohydrate |
|---|
| 活性成分 | bosentan (as monohydrate) |
|---|
| 产品号 | EMEA/H/C/002644 |
|---|
| 患者安全信息 | No |
|---|
| 许可状态 | Authorised |
|---|
| ATC编码 | C02KX01 |
|---|
| 是否额外监管 | No |
|---|
| 是否仿制药或hybrid药物 | No |
|---|
| 是否生物类似药 | No |
|---|
| 是否附条件批准 | No |
|---|
| 是否特殊情形 | No |
|---|
| 是否加速审评 | No |
|---|
| 是否罕用药 | No |
|---|
| 上市许可日期 | 2013/06/24 |
|---|
| 上市许可开发者/申请人/持有人 | Janssen-Cilag International NV |
|---|
| 人用药物治疗学分组 | Other antihypertensives |
|---|
| 兽用药物治疗学分组 | |
|---|
| 审评意见日期 | 2013/03/21 |
|---|
| 欧盟委员会决定日期 | 2024/10/22 |
|---|
| 修订号 | 18 |
|---|
| 治疗适应症 | Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with World Health Organization (WHO) functional class III. Efficacy has been shown in: primary (idiopathic and familial) PAH; PAH secondary to scleroderma without significant interstitial pulmonary disease; PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s physiology. Some improvements have also been shown in patients with PAH WHO functional class II. Stayveer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital-ulcer disease. |
|---|
| 适用物种 | |
|---|
| 兽用药物ATC编码 | |
|---|
| 首次发布日期 | 2017/09/26 |
|---|
| 最后更新日期 | 2024/10/24 |
|---|
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/stayveer-epar-product-information_en.pdf |
|---|
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/stayveer |
|---|